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1. Introduction
The statement is an update of the original document first
published in the Southern African Journal of Critical Care in 2001,1
which was necessitated by the recent licensing of the newest
member of this class of antibiotics, ertapenem. 
Ertapenem is the first of a new group of carbapenems, which
differ significantly from the earlier agents.2,3 The activity of
ertapenem, similar to that of the earlier agents, includes amp-C
beta-lactamase, extended spectrum beta-lactamase (ESBL)-
producing pathogens and anaerobes. However, it has only
marginal activity against non-fermentative Gram-negative
bacilli. This spectrum is more suitable for the treatment of
severe infections acquired outside the hospital and certain
hospital-acquired infections, where Pseudomonas spp. and/or
Acinetobacter spp. are not suspected.  Furthermore, the
appropriate use of this agent in these settings may help to
reduce selective pressure for resistance development in the
latter pathogens. An additional differentiating characteristic of
ertapenem is its once-daily intravenous or intramuscular
dosing, compared with the multiple dosing required for the
earlier agents.
Imipenem/cilastatin and meropenem have a broad spectrum
of activity against a number of bacterial species, including non-
fermentative Gram-negative bacteria such as Pseudomonas and
Acinetobacter spp. This makes them ideal for the treatment of
severe nosocomial infections. 
Based on these differences Shah and Isaacs3 have proposed
the following carbapenem classification scheme.
• Group 1 includes broad-spectrum carbapenems, with
limited activity against non-fermentative Gram-negative
bacilli, that are particularly suitable for  community-
acquired infections (e.g. ertapenem).
• Group 2 includes broad-spectrum carbapenems, with
activity against non-fermentative Gram-negative bacilli, that
are particularly suitable for nosocomial infections (e.g.
imipenem and meropenem).
• Group 3 includes carbapenems with clinical activity
methicillin-resistant Staphylococcus aureus (none currently
licensed).
2. Ertapenem (group 1) 
2.1 Appropriate use
• This agent is most appropriately used for the treatment of
severe community-acquired infections.   However, the
agent should not be used as first-line empirical therapy,
except in certain specific circumstances. 
• This agent may be also be used in a few specific instances
for nosocomial infections where Pseudomonas spp. are not
deemed important pathogens, such as early nosocomial
pneumonia acquired out of the intensive care unit (ICU).
• This agent is ideal for directed therapy based on the results
of microbiological testing, and especially for the treatment
of infections with isolates demonstrating ESBLs.
• This agent is well suited for the treatment of chronic and
recurrent or persistent infections in cases in which cultures
are most likely to demonstrate resistant Enterobacteriaceae
or that are polymicrobial in nature; however, it is not
effective against Pseudomonas and Acinetobacter spp. 
• It is indicated for the treatment of the following infections,
with specific indications: 
• Pneumonia
• Surgical infections including intra-abdominal, skin and
soft-tissue and gynaecological infections
• Urinary tract infections.
Please forward all comments to: Dr A J Brink, PO Box 1873, Houghton, 2041, 
tel. (011) 726-6260, e-mail brinka@ampath.co.za
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The carbapenems are a group of broad-spectrum beta-
lactam antibiotic agents of which there are three parenteral
preparations currently available in South Africa, namely
imimpenem/cilastatin, meropenem and ertapenem. Owing
to the fact that imipenem/cilastatin and meropenem have a
broad spectrum of activity that includes Pseudomonas and
Acinetobacter species, they are ideal antibiotics for treatment
of severe nosocomial infections. In contrast, ertapenem has
limited in vitro activity against the latter non-fermentative
Gram-negative bacteria and is therefore more suitable for
the treatment of certain severe community-acquired
infections. This statement arises out of concerns about the
general abuse of antibiotics such as the carbapenems, with
the primary intention of highlighting the appropriate use of
these agents.
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2.2 Pneumonia (Table I)
2.2.1 Appropriate use in pneumonia
In the case of pneumonia, this agent may be indicated in the
following circumstances:
• The elderly, especially high risk-cases with underlying co-
morbid illness and/or those living in long-term care
facilities (LTCF) or in alcoholics where no risk factors for
pseudomonal infections are present.*
• Hospital-acquired pneumonia where no risk factors for
pseudomonal infections are present.*
• Nosocomial aspiration pneumonia/suspected anaerobic
infection/lung abscess such as may occur in patients with
neurological disorders or swallowing dysfunction.
• Cases known to be, or suspected of being, infected with
pathogens resistant to standard antimicrobial agents but
retaining susceptibility to ertapenem, especially in cases
where Gram-negative pathogens are involved.  
• Patients who have failed standard first-line antibiotic
therapy for community-acquired pneumonia particularly as
part of directed antibiotic therapy based on the results of
microbiological testing.
1.2.2 Inappropriate use in pneumonia
• This agent should not be used for empirical therapy of
nosocomial pneumonia in the ICU. 
• This agent should not be used for first-line, empirical
therapy of community-acquired pneumonia. 
• This agent should not be used for the empirical treatment of
pneumonia in patients at risk of pseudomonal infections.*
2.3 Surgical infections (Table II)
2.3.1 Appropriate use in intra-abdominal infections
In the case of community-acquired intra-abdominal surgical
infections, this agent could be used for treatment of patients in
the following settings:
• Severe sepsis, e.g. patients with organ dysfunction,
requiring inotropes, with an Acute Physiology and Chronic
Health Evaluation (APACHE II) score > 20 or requiring ICU
admission for conditions such as:
• Acute appendicitis, ruptured or perforated appendix and
peri-appendiceal abscess
• Acute diverticulitis with perforation and/or abscess
• Acute cholecystitis (including gangrenous) with either
rupture or perforation
• Acute gastric and duodenal perforation
• Traumatic perforation of the intestine
• Intra-abdominal abscess including liver and spleen.
• Cases at risk of having ESBL-producing and/or
fluoroquinolone-resistant micro-organisms, e.g. LTCF
residents; this should be culture driven as these patients are
also at risk of Pseudomonas and Acinetobacter spp. infections.
• As part of directed therapy in cases with isolates
Table I. Ertapenem (group 1) — pneumonia 
Appropriate use Inappropriate use
• The elderly, especially high-risk cases with underlying • Empirical treatment of nosocomial  pneumonia in the ICU
co-morbid illness and patients living in long-term care facilities • First-line, empirical treatment of CAP
where no risk factors  for pseudomonal infections are present* • Presence of risk factors for pseudomonal infections* 
• Alcoholics
• Hospital-acquired pneumonia where no risk factors for 
pseudomonal  infections are present* 
• Nosocomial aspiration pneumonia/suspected anaerobic  
infection/lung abscess
• Cases known to be, or suspected of being, infected with 
pathogens resistant to standard antimicrobial agents, 
particularly extended-spectrum β-lactamase-producing GNB
• Patients who have failed standard first-line antibiotic treatment for CAP
(particularly as part of directed antibiotic therapy based on the 
results of microbiological testing)
*Risk factors for pseudomonal infections may include:
Infections acquired in the ICU
Patients with structural lung disease
Patients who have received broad-spectrum antibiotic Rx  for > 7 days in the previous month
Patients who have recently been hospitalised (because of  nosocomial colonisation)
GNB = Gram-negative bacilli; CAP = community-acquired pneumonia.
*Risk factors for pseudomonal infections may include:4-7
• Infections acquired in the ICU
• Patients with structural lung disease, in particular patients with cystic fibrosis
and/or bronchiectasis
• Patients who have received broad-spectrum antibiotic therapy for more than 7
days in the previous month
• Patients who have recently been hospitalised (because of nosocomial
colonisation).
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demonstrating the presence of ESBLs and/or based on the
results of other microbiological testing, including evidence
of polymicrobial infections.
2.3.2 Appropriate use in skin and soft-tissue infections
In the case of community-acquired skin and soft-tissue surgical
infections, this agent should be reserved for treatment of
patients in the following settings:
• Severe cases of established necrotising fasciitis or Fournier's
gangrene requiring ICU admission.
• Cases at risk of having ESBL-producing and/or
fluoroquinolone-resistant micro-organisms, e.g. LTCF
residents. 
• As part of directed therapy in cases with isolates
demonstrating the presence of ESBLs and/or based on the
results of microbiological testing including evidence of
polymicrobial infections.
• As directed out-patient monotherapy in cases with
confirmed polymicrobial and/or resistant infections, e.g.
LTCF residents.
2.3.3 Inappropriate use in surgical infections 
• This agent should not be used for the empirical treatment of
nosocomial intra-abdominal infections, particularly not in
cases with prolonged pre-operative length of hospital stay
and prolonged pre-operative antimicrobial therapy (more
than 2 days); these factors are significant predictors of
antibiotic failure resulting in recurrent infection.8
• This agent should not be used in community-acquired intra-
abdominal infections in patients at high risk of post-
operative mortality, where the presence of infection with
multiresistant bacteria including Pseudomonas spp. might be
common. In these high-risk patients, use of broader-
spectrum, antipseudomonal antibiotics may be warranted:9,10
• Immunosupression resulting from prior therapy for
transplantation, cancer or inflammatory diseases
• Prior hospitalisation (as late-onset sequelae of
nosocomial colonisation).
• This agent should not be used for mild skin and soft-tissue
infections.
• This agent should not be used as directed therapy for
infections caused by S. aureus, whether due to methicillin-
sensitive or resistant isolates.
2.4 Urinary tract infections (Table III)
2.4.1 Appropriate use in urinary tract infections
• This agent is indicated for the treatment of severe,
complicated urinary tract infections particularly in cases at
risk of having resistant Gram-negative pathogens.
• As part of directed therapy in cases with isolates
demonstrating the presence of ESBLs and/or based on the
results of microbiological testing.
859
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Table II. Ertapenem (group 1) — surgical infections
Appropriate use Inappropriate use
Intra-abdominal infections (IAIs)
• Severe community-acquired IAI in patients with organ • Empiric treatment of nosocomial IAI
dysfunction, requiring inotropes, with an APACHE II score • Community-acquired IAI at risk of infection with
> 20 or requiring ICU admission Pseudomonas spp:
• Cases at risk of having ESBL-producing and/or  • Prior hospitalisation (as late-onset sequelae of nosocomial 
fluoroquinolone-resistant micro-organisms, e.g. LTCF colonisation) 
residents (this should be culture-driven as these patients • Immunosupression resulting from prior therapy  for transplantation, 
are also at risk of Pseudomonas and Acinetobacter spp. infections) cancer or inflammatory diseases
•  Directed treatment in cases with isolates demonstrating the 
presence of ESBL and/or based on the results of other 
microbiological testing, including evidence of polymicrobial 
infections
Skin and soft-tissue infections
• Severe cases of community-acquired necrotising fasciitis or • Mild skin and soft-tissue infections
Fournier’s gangrene requiring ICU admission • Directed treatment for infections caused by Staphyloccus aureus,
• Severe cases at risk of having ESBL-producing and/or whether due to methicillin-sensitive or resistant isolates
fluoroquinolone-resistant micro-organisms e.g. LTCF residents
• As part of directed treatment in cases with isolates demonstrating 
the presence of ESBLs and/or based on the results of 
microbiological testing including evidence of polymicrobial
infections
• As directed outpatient monotherapy in cases with confirmed 
polymicrobial and/or resistant infections, e.g. LTCF residents
ESBL = extended spectrum beta-lactamase; LTCF = long-term care facility.
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2.4.2 Inappropriate use in urinary tract infections
• This agent should not be used for first-line, empirical
therapy of community-acquired urinary tract infections.
2.5 Other considerations for ertapenem therapy
• This agent may be used as therapy for infections acquired in
the ICU, but only as part of directed therapy based on
results of microbiological testing, and especially for the
treatment of infections with isolates demonstrating ESBLs.
• There is emerging evidence that shorter duration of therapy
is as effective as longer therapy and has the potential benefit
of less impact on resistance development.
• If indicated for cases of severe community-acquired
pneumonia, empirical treatment with this agent should be
combined with a macrolide or fluoroquinolone until culture
results become available.
3. Imipenem/cilastatin and meropenem
(group 2) (Table IV)
3.1 Appropriate use
• These agents are most appropriately used for the early,
timeous treatment of severe nosocomial infections in the
critically ill patient or in the critical care setting, particularly
when no other antibiotic appears to be suitable, or is
available. In this setting these agents may be used as
empirical therapy for severe nosocomial infections, based on
knowledge of local surveillance data from a particular unit.
They may also be suitable for use where first-line empirical
therapy against Gram-negative organisms has failed.
• They should ideally be used as specific antibiotic therapy
directed against significant isolates cultured from
appropriate specimens, and should be prescribed according
to the results of antibiotic susceptibility testing. This is
where close interaction with the clinical microbiologist and
the microbiology laboratory will be of major assistance.
• These agents may be necessary for antibiotic therapy of
certain conditions in which there is chronic pseudomonal
infection, such as bronchiectasis, cystic fibrosis, and
immune deficiency disorders.  Where these agents are used
for the therapy of patients with pseudomonal infection in
frail care settings, this should be done with consideration of
the results of culture and sensitivity testing and they should
not be considered as first-line therapy.
• Although not considered as primary therapy in most cases,
these agents may be considered for use in neutropenic
sepsis, severe abdominal sepsis in certain specific settings,
and meningitis. The carbapenem recommended for the
treatment of meningitis is meropenem.
3.2 Inappropriate use
• Neither of these agents is indicated for the routine treatment
of otitis media, acute exacerbations of chronic bronchitis,
surgical prophylaxis or first-line treatment of community-
acquired infections, such as pneumonia or gynaecological or
urological infections.
• Although these two agents provide Gram-positive cover,
they are not indicated for the treatment of nosocomial or
community-associated Gram-positive sepsis. 
• Unnecessary use of these carbapenems, particularly in the
ICU setting, may select for multiresistant and difficult-to-
treat infections, such as Stenotrophomonas maltophilia,
Burkholderia spp., etc.
3.3 Other considerations
• Monotherapy with these carbapenems is suitable in most
circumstances, but where infections with Pseudomonas spp.
are suspected or proven, particularly bacteraemic infections,
combination therapy together with an aminoglycoside or an
appropriate fluoroquinolone (e.g. ciprofloxacin) may be
considered.
Table III. Ertapenem (group 1) — urinary tract infections
(UTIs)
Appropriate use Inappropriate use
• Severe, complicated UTI • First-line empirical treatment
particularly in cases at risk of of community-acquired UTI
having resistant pathogens 
including ESBL- producing GNB, 
e.g. LTCF residents 
ESBL = extended spectrum beta-lactamase; GNB = Gram negative bacilli; 
LTCF = long-term care facility. 
Table IV. Imipenem/cilastatin and meropenem (group 2)
Appropriate use Inappropriate use
• Empiric treament of severe • Routine treatment of otitis media
nosocomial infections in • Routine treatment of acute
critically ill patients or in ICU exacerbations of chronic
• Failure of first-line bronchitis
antibiotics for Gram-negative • Surgical prophylaxis
bacterial (GNB) infections • Routine treatment of
• Directed treatment according to community-acquired
results of culture and pneumonia (CAP)
susceptibility testing • Routine treatment of
• Chronic multiresistant community-acquired
pseudomonal infections gynaecological infections
• In certain settings of • Routine treatment of
neutropenic sepsis, severe community-acquired 
nosocomial intra-abdominal urological infections
sepsis and meningitis • Nosocomial or community-
acquired Gram-positive sepsis 
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• The use of metronidazole or other anti-anaerobic agents
together with these carbapenems is not necessary except in
the case of infections with Clostridium difficile.
• Appropriate therapeutic dosing is essential since
underdosing in the face of high minimum inhibitory
concentrations (MICs) may be associated with decreased
efficacy and increased resistance. Monitoring of the MIC is
useful in that it may indicate future antibiotic susceptibility
trends and may influence dosing. This is an area in which
the advice of the clinical microbiologist is particularly
helpful.
• There is emerging evidence that shorter duration of therapy
for certain nosocomial infections such as ventilator-
associated pneumonia is as effective as longer therapy and
has the potential benefit of reducing the incidence of
hospital-acquired superinfection or reinfection with
multiresistant bacteria or Candida spp., while
simultaneously reducing antibiotic pressures.
• Because of the risk of selecting for resistance, initial
empirical broad-spectrum treatment with imipenem or
meropenem should be ‘de-escalated’ or ‘tailored’ to a
narrow-spectrum agent, once the identity and susceptibility
profiles of the infecting pathogens are known. If a less
resistant pathogen is identified, it should be mandatory to
de-escalate antibiotic therapy with these carbapenems to an
agent with a narrower spectrum of activity.
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